Nathenson v. Zonagen Inc.

REVISED OCTOBER 15, 2001

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 99-20449

JAMES M. NATHENSON, on behalf of

himself and all others similarly situated;

DSAM GLOBAL VALUE FUND LTD; JONATHAN

MARGALIT; AMIT SANGHVI; JIANBO XIE;

JOHN DEROSA; ROBERT STRASSMAN;

DEAN HAGEN; ARNO HAUSMANN,

Plaintiffs-Appellants,

versus

ZONAGEN INC; ET AL,

Defendants,

ZONAGEN INC; JOSEPH PODOLSKI;

STEVEN BLASNIK; M SUTTER,

Defendants-Appellees.

Appeal from the United States District Court

for the Southern District of Texas, Houston

September 25, 2001

Before GARWOOD, DeMOSS, and PARKER, Circuit Judges.

GARWOOD, Circuit Judge:

Plaintiffs-appellants James Nathenson and others (collectively, the

plaintiffs) filed this putative class action in the court below against

defendants-appellants Zonagen, Inc. (Zonagen), Zonagen chief executive

officer and director Joseph Podolski (Podolski) and Zonagen outside

directors and major shareholders Steven Blasnik (Blasnik) and Martin

Sutter (Sutter) (collectively, the defendants). In their complaint, the

plaintiffs sought class certification and alleged violations of sections

10(b) and 20(a) of the Securities Exchange Act of 1934 (1934 Act) and

Rule 10b-5 of the Securities Exchange Commission (SEC). The defendants

moved to dismiss the complaint under FED. R. CIV. P. 12(b)(6). The

district court granted the motion in a memorandum opinion and in a

separate document rendered judgment that “this action is dismissed with

prejudice.” The plaintiffs now appeal. Finding sufficient merit in

one of plaintiffs’ complaints on appeal, we vacate and remand.

Facts and Proceedings Below

This is a private securities fraud action brought by nine

putative class representatives on behalf of purchasers of common

stock in Zonagen, a biopharmaceutical company based in The

Woodlands, Texas. The plaintiffs allege that during the class

period,1 February 7, 1996, through January 9, 1998, the

defendants–Zonagen, its president and CEO, Podolski, and two of its

outside directors and major shareholders, Blasnik and Sutter, the

latter being Chairman of the Board, engaged in a scheme to defraud

their shareholders by issuing a series of public misrepresentations

1

In their Consolidated Amended Complaint, the plaintiffs sought

class certification under FED. R. CIV. P. 23. However, the district

court granted the defendants’ motion to dismiss before ruling on the

certification issue. Despite the absence of certification, we will, for

clarity’s sake, refer to the time in question as the “class period.”

2

about two of Zonagen’s potential products in order to inflate

artificially the value of Zonagen’s stock and sell $67.5 million in

stock in July 1997 at an inflated price. The two potential

products in question are “Vasomax,” an oral treatment for male

erectile dysfunction (MED), and “Immumax,” an adjuvant2 for the

delivery of animal and human vaccines.

In order to market a drug in the United States, developers

must first obtain the approval of the Food and Drug Administration

(FDA). This approval process involves, among other things,

conducting a series of clinical trials to establish the safety and

efficacy of the drug. The maker of the drug then submits the

results of these trials to the FDA as part of its New Drug

Application (NDA). Phase I trials test the safety, dosage

tolerance, and other pharmacokinetic properties of the drug; they

also identify the primary side-effects, if any, that the drug may

cause. During Phase II trials, researchers test the drug in a

limited patient population to gather information about efficacy,

optimal dosage levels, adverse effects, and safety risks. Phase

III trials test the efficacy and safety of the drug in an expanded

patient population at geographically dispersed trial sites.

The broad contours of the events in question are as follows.

2

An adjuvant a is foreign substance that improves a given

immune response in the body by enhancing the effect of a particular

antigen, which is a substance that stimulates the production of

antibodies. See STEDMAN’S MEDICAL DICTIONARY 29 (Marjory Spraycar ed.,

26th ed. 1995).

3

In 1995, Zonagen completed its Phase I trials for Vasomax in

Ireland and reported the results of these trials in a Form 10-K

filed with the SEC that year. The company then initiated Phase II

trials in Germany; these trials concluded in March 1996. On

February 7, 1996, the first day of the class period, Zonagen shares

traded at $12 3/8. On February 7 and 14, 1996, before the

completion of the Phase II trials, two news items appeared in which

Podolski indicated that the “preliminary” results of the Phase II

trials were positive. Similar statements were made to analysts on

March 5 and in a March 14, 1996 press release (similar statements

were also made in Zonagen’s April 1, 1996 10K for the year ended

December 31, 1995). The stock traded at $16 a share on March 13,

1996. On May 9 and 16, 1996, Zonagen issued press releases that

described the Phase II results in positive terms, the May 9 release

unmistakably implying and the May 16 release expressly stating that

the Phase II trials produced statistically significant results. As

the district court noted, Zonagen shares after March 13, 1996 “fell

steadily until reaching . . . less than $10 per share in early

August.”

In press releases, as well as in its public filings with the

SEC, Zonagen represented not only that the Phase II trials had

positive results, but also that Zonagen had acquired the rights to

a “method of use” patent, known as the Zorgniotti patent, which

covered the administration of phentolamine, the active ingredient

4

in Vasomax. In addition, Zonagen used its press releases and

public filings of 1996-97 to state its belief that it had

“discovered” a “new” adjuvant, which it called Immumax.

In November 1996, Zonagen began Phase III trials for Vasomax

in the United States. Soon after, Zonagen began issuing press

releases discussing these trials and expressing its hope that the

results would enable Zonagen to file an NDA by June 1997. In its

public filings with the SEC, it made similar statements about the

Phase III trials in the United States. On November 14, 1996,

Zonagen filed a Form S-3 with the SEC in connection with the

proposed sale by some of its shareholders of Zonagen shares not

previously publicly offered. In the Form S-3, Zonagen disclosed

that the Phase II trials had not yielded statistically significant

results and that the other patent (the Lowrey patent) it had hoped

would cover Vasomax had been rejected in a non-final first office

action by the United States Patent and Trademark Office.

In 1997, Zonagen’s press releases and public filings noted the

positive results of the Phase III trials. On June 11, 1997,

Zonagen filed a Form S-3 with the SEC seeking registration of two

million shares of Zonagen stock for sale by the company. The Form

S-3 stated that the Phase III trials had yielded statistically

significant results, and also discussed the “discovery” of Immumax

and the Zorgniotti patent respecting Vasomax. On June 13, 1997,

Zonagen issued a press release announcing the successful completion

5

of its Phase III trials. On May 23, 1997, the last day of trading

before the announcement, the price per share of Zonagen stock was

$17d. On May 27, the day of the announcement, the price per share

rose to $24½. On July 18, 1997, after no further announcements,

Zonagen’s share price closed at $32¼. On July 22, 1997, Zonagen

filed a prospectus with the SEC which commenced its secondary

offering of common stock. In a press release issued that same day,

the company announced that it had raised $67.5 million in gross

proceeds from the sale of 2.25 million shares sold at a price of

$30 per share. Zonagen shares rendered a high of 44 3/8 on October

13, 1997. On January 12, 1998, the Monday following January 9,

1998, the last day of the class period, the stock closed at 13

15/16. The average closing price of Zonagen shares in the ninety

days following the last day of the class period (January 9, 1998

through April 10, 1998) was $20 1/5. On June 2, 1998, the stock

traded at $36 3/4 per share; by June 12, 1998, it had fallen to $24

3/4 per share.3

On June 19, 1998, the plaintiffs filed their Consolidated

Amended Complaint (complaint) seeking class certification and

3

The above stated information as to share prices comes from the

amended complaint and its attachments. Defendants also furnished the

district court with a list covering all trading days from March 25, 1993

through July 30, 1998 showing the Zonagen high ask, low bid and close

bid prices and volume each day. The accuracy of that information has

not been questioned.

6

alleging that the defendants had violated section 10(b)4 of the

1934 Act and Rule 10b-55 promulgated thereunder by the SEC (an

original complaint was filed March 9, 1998). The plaintiffs also

contended that the three individual defendants were liable as

“controlling persons” under section 20(a)6 of the 1934 Act. As

noted above, the complaint primarily charges that the defendants

made a series of misrepresentations about their Vasomax and Immumax

potential products in order to artificially inflate the company’s

share price, and then sold a large amount of stock at an inflated

4

Section 10(b) provides in relevant part:

“It shall be unlawful for any person, directly or indirectly

. . .

(b) To use or employ, in connection with the purchase or sale

of any security . . any manipulative or deceptive device or

contrivance in contravention of such rules and regulations as

the [SEC] may prescribe as necessary or appropriate in the

public interest or for the protection of investors.” 15 U.S.C.

§ 78j(b).

5

Rule 10b-5 provides in relevant part:

“It shall be unlawful for any person, directly or indirectly

. . .

(b) To make any untrue statement of a material fact or to omit

to state a material fact necessary in order to make the

statements made, in the light of the circumstances under which

they were made, not misleading . . . in connection with the

purchase or sale of any security.” 17 C.F.R. § 240.10b-5.

6

Section 20(a) of the 1934 Act provides in relevant part:

“Every person who, directly or indirectly, controls any person

liable under any provision of this chapter . . . shall also be

liable jointly and severally with and to the same extent as

such controlled person.” 15 U.S.C. § 78t(a).

7

price. On August 3, 1998, the defendants moved to dismiss the

complaint pursuant to FED. R. CIV. P. 12(b)(6). On March 31, 1999,

the district court granted the motion and dismissed the “action”

with prejudice. The plaintiffs now appeal.

Discussion

On appeal, the plaintiffs maintain that the district court erred

in dismissing their complaint.

This Court reviews a district court’s dismissal under Rule 12(b)(6)

de novo. See Rubenstein v. Collins, 20 F.3d 160, 166 (5th Cir. 1994).

In doing so, we will accept the facts alleged in the complaint as true

and construe the allegations in the light most favorable to the

plaintiffs. See id. (citing Scheuer v. Rhodes, 94 S.Ct. 1683, 1686

(1974)).

I. Private Securities Litigation Reform Act

As a preliminary matter, we note that this case presents us

with the occasion to apply the Private Securities Litigation Reform

Act of 1995 (PSLRA), Pub. L. 104-67, 109 Stat. 737 (December 22,

1995), which Congress passed to prevent the abuse of federal

securities laws by private plaintiffs. The statute purports to

increase the pleading requirement for plaintiffs alleging section

10(b)/Rule 10b-5 claims.

A. “Strong” Inference of Scienter

In order to state a claim under section 10(b) of the 1934 Act

and Rule 10b-5, a plaintiff must allege, in connection with the

8

purchase or sale of securities, “(1) a misstatement or an omission

(2) of material fact (3) made with scienter (4) on which plaintiff

relied (5) that proximately caused [the plaintiffs’] injury.”

Tuchman v. DSC Communications Corp., 14 F.3d 1061, 1067 (5th Cir.

1994) (quotation omitted). Before the passage of the PSLRA, the

Courts of Appeals had not reached a consensus regarding the nature

and content of the allegations of scienter that a plaintiff must

plead in order to survive a motion to dismiss. See Bryant v. Avado

Brands, Inc., 187 F.3d 1271, 1282 (11th Cir. 1999). Interpreting

FED. R. CIV. P. 9(b), which requires plaintiffs alleging fraud to

plead “with particularity” the circumstances supporting their

allegations, the Second Circuit held that securities fraud

plaintiffs must allege specific facts giving rise to a “strong

inference” of scienter, while the Ninth Circuit allowed plaintiffs

to plead scienter generally. See id. (citing cases). At that

time, the Second Circuit’s “strong inference” test was the most

stringent among the Courts of Appeals. This Court also required

plaintiffs to plead specific facts, but unlike the Second Circuit,

only mandated that the specific facts alleged “support an inference

of fraud.” See Tuchman, 14 F.3d at 1068.

Unsatisfied with the disagreement among the Circuits, as well

as the perceived inability of Rule 9(b) to prevent abusive,

frivolous strike suits, Congress in 1995 passed the PSLRA over the

President’s veto. See H.R. Conf. Rep. No. 104-369, at 41 (1995),

9

reprinted in 1995 U.S.C.C.A.N. 730, 740. The PSLRA amended the

1934 Act to provide in relevant part:

“In any private action arising under this chapter in

which the plaintiff may recover money damages on proof

that the defendant acted with a particular state of mind,

the complaint shall, with respect to each act or omission

alleged to violate this chapter, state with particularity

facts giving rise to a strong inference that the

defendant acted with the required state of mind.” 15

U.S.C. § 78u-4(b)(2).

The PSLRA also provides that if a plaintiff does not meet this

requirement, the district court “shall,” on defendant’s motion,

“dismiss the complaint.” See id. § 78u-4(b)(3).

The plain language of the statute makes clear that our

previous rule, which required that a plaintiff plead facts that

merely “support an inference of fraud,” has been supplanted by the

PSLRA’s “strong inference” requirement. We therefore find that in

order to survive a motion to dismiss, a plaintiff alleging a

section 10(b)/Rule 10b-5 claim must now plead specific facts giving

rise to a “strong inference” of scienter.

B. Severe Recklessness as a “Required State of Mind” Post-

PSLRA

The PSLRA leaves undefined, however, the content of the

scienter requirement, that is, “the required state of mind”

necessary to allege a private securities fraud claim. The absence

of direct guidance on this point, coupled with the statute’s stated

purpose of winnowing out meritless claims by imposing more

stringent pleading requirements on plaintiffs, has raised in the

10

minds of some the possibility that the PSLRA may have eliminated

the lesser mental state of recklessness as a basis for liability.

Based on the language of the statute, we conclude that the PSLRA

does not purport to, and does not, speak to or address the state of

mind generally required to impose liability under section 10(b) and

Rule 10b-5, and hence, with certain specific exceptions, does not

itself eliminate the possibility that recklessness may suffice.

Accordingly, and apart from those below noted specific instances

where the matter is addressed by the PSLRA, whether recklessness

suffices for such purpose is governed by our pre-PSLRA

jurisprudence.

In Ernst & Ernst v. Hochfelder, 96 S.Ct. 1375, 1381 n.12

(1976), the Supreme Court defined scienter for purposes of

securities fraud cases as “a mental state embracing intent to

deceive, manipulate, or defraud.” The Court left open the question

whether scienter included recklessness. See id.7 Since that

time, and prior to the PSLRA, the Courts of Appeals, including this

Court, have held that recklessness does satisfy the scienter

requirement. See Hollinger v. Titan Capital Corp., 914 F.2d 1564,

1569-70 (9th Cir. 1990); In re Phillips Petroleum Sec. Litig., 881

F.2d 1236, 1244 (3d Cir. 1989); Van Dyke v. Coburn Enter. Inc., 873

F.2d 1094, 1100 (8th Cir. 1989); McDonald v. Alan Bush Brokerage

7

The Court made it clear, however, that negligence alone is

insufficient to support liability. See id. at 1384.

11

Co., 863 F.2d 809, 814 (11th Cir. 1989); Hackbart v. Holmes, 675

F.2d 1114, 1117-18 (10th Cir. 1982); Broad v. Rockwell, 642 F.2d

929, 961-62 (5th Cir. 1981) (en banc); Mansbach v. Prescott, Ball

& Turben, 598 F.2d 1017, 1023-24 (6th Cir. 1979); Rolf v. Blyth,

Eastman Dillon & Co., 570 F.2d 38, 47 (2d Cir. 1978); Sundstrand

Corp. v. Sun Chem Corp., 553 F.2d 1033, 1044 (7th Cir. 1977).

Adopting the definition first announced in Sundstrand, this

Court and other Courts of Appeals have conceived of recklessness in

this context as “severe recklessness,” which, “properly defined and

adequately distinguished from mere negligence,” resembles a

slightly lesser species of intentional misconduct. See Broad, 642

F.2d at 961. This Court defined recklessness as “limited to those

highly unreasonable omissions or misrepresentations that involve

not merely simple or even inexcusable negligence, but an extreme

departure from the standards of ordinary care, and that present a

danger of misleading buyers or sellers which is either known to the

defendant or is so obvious that the defendant must have been aware

of it.” Id. at 961-62.

It seems clear to us that the PSLRA has not generally altered

the substantive scienter requirement for claims brought under

section 10(b) and Rule 10b-5, and therefore severe recklessness, as

defined in Broad, remains a basis for such liability. The First,

Third, Sixth, and Eleventh Circuits have all explicitly reached

similar conclusions. See Greebel v. FTP Software, Inc., 194 F.3d

12

185, 198-201 (1st Cir. 1999); In re Advanta Corp. Sec. Litig., 180

F.3d 525, 534 (3d Cir. 1999); In re Comshare, Inc. Sec. Litig.,

183 F.3d 542, 548-49 (6th Cir. 1999); Bryant, 187 F.3d at 1283-84.8

The Second Circuit has implicitly so concluded as well. See Novak

v. Kasaks, 216 F.3d 300, 306 (2d Cir. 2000) (observing that the

scienter requirement for securities fraud claims, which includes

recklessness, “has been firmly established for at least a

generation” and that the PSLRA altered the “procedural”

requirements for bringing such a claim); see also Rothman v.

Gregor, 220 F.3d 81, 90 (2d Cir. 2000) (describing substantive

recklessness standard). The Ninth Circuit has reached the slightly

different conclusion that, at least under the PSLRA, recklessness

suffices to meet the substantive scienter requirement only if it

rises to the level of “deliberate recklessness.” See In re Silicon

Graphics Inc. Sec. Litig., 183 F.3d 970, 975-77 (9th Cir.), reh’g

and reh’g en banc denied, 195 F.3d 521 (9th Cir. 1999).

As the Third Circuit has pointed out, the PSLRA characterizes

the requirements of section 78u-4(b)(2) as a “pleading

requirement,” not as a change to the substantive scienter

requirement. See Advanta, 180 F.3d at 534 (citing section 87u-

8

The Fourth Circuit has also apparently reached this

conclusion, however obliquely. See Phillips v. LCI Int’l, Inc.,

190 F.3d 609, 620 (4th Cir. 1999) (“Thus, to establish scienter, a

plaintiff must still prove the defendant acted intentionally, which

may perhaps be shown by recklessness.”).

13

4(b)(3)). The legislative history confirms this point and

demonstrates that the floor debates, the committee reports from

both houses of Congress, and the President’s veto statement all

describe the PSLRA as imposing “pleading” or “procedural”

requirements. See id.; see also Greebel, 194 F.3d at 200 (noting

that neither the legislative history nor the language of the PSLRA

evinces an intent to change the generally applicable substantive

definition of scienter). Further, as noted above, the PSLRA does

not define the generally “required state of mind” for private

securities fraud cases, but rather requires that a plaintiff plead

facts giving rise to a “strong inference” of “the required” state

of mind.

Moreover, Congress specified a substantive state of mind

requirement elsewhere in the statute, in the statutory safe harbor

provisions for “forward-looking statements” and joint and several

liability. See 15 U.S.C. § 78u-5(c)(1)(B) (creating safe harbor

for such statements if plaintiff cannot demonstrate that they were

made with “actual knowledge” that the statements were false or

misleading at the time they were made); id. § 78u-4(f)(2)(A)

(limiting joint and several liability to defendants whose action

has been found to be “knowing”). “If Congress desired to require

some other state of mind [for purposes of section 78u-4(b)(2)],

that is, other than the reckless state of mind then uniformly held

sufficient by the federal courts . . . Congress [could] have done

14

so in explicit terms” as it did with these provisions. Bryant, 187

F.3d at 1284; see also Greebel, 194 F.3d at 200 (“Congress, having

explicitly eliminated recklessness as a basis for imposing joint

and several liability, should not be taken as implicitly having

eliminated recklessness as a basis for any liability.”).

Accordingly, we join the First, Third, Sixth, and Eleventh

Circuits and conclude that recklessness, the “severe recklessness”

defined in Broad, still constitutes scienter for purposes of claims

brought under section 10(b) and Rule 10b-5 (except as otherwise

provided in the noted statutory safe harbor provisions respecting

forward looking statements and joint and several liability).

C. Pleading Requirement for Scienter Under the PSLRA

The next inquiry is what effect the PSLRA has on the patterns

of facts that may be pleaded in order to create the “strong

inference” of either intentional misconduct or severe recklessness.

Before Congress passed the PSLRA, the Second Circuit announced two

means by which a plaintiff could plead facts that would create a

strong inference of scienter: the plaintiff could either (1) allege

facts to show that a defendant had both motive and opportunity to

commit fraud, or (2) allege facts that constitute strong

circumstantial evidence of conscious misbehavior or recklessness.

See Shields v. Citytrust Bancorp, Inc., 25 F.3d 1124, 1128 (2d Cir.

1994). This Court apparently adopted these two formulations as

well, although for the former, we indicated that a plaintiff could

15

satisfy the scienter requirement at the pleading stage “by alleging

facts that show a defendant’s motive to commit securities fraud.”

Tuchman, 14 F.3d at 1068. During the passage of the PSLRA, there

was considerable debate in Congress over whether the PSLRA

effectively incorporated the prior Second Circuit methods for

proving scienter or prohibits at least the use of the motive and

opportunity method. See Greebel, 194 F.3d at 194. The parties

address this debate as well, with the plaintiffs, and the SEC as

amicus, arguing that the motive and opportunity method survived the

passage of the PSLRA, and the defendants urging a more restrictive

view. The district court did not decide this question because it

concluded that the plaintiffs could not meet either method of

pleading scienter.

There does not appear to be any question that under the PSLRA

circumstantial evidence can support a strong inference of scienter.

As the First Circuit has pointed out, “Congress plainly

contemplated that scienter could be proven by inference, thus

acknowledging the role of indirect and circumstantial evidence.”

Greebel, 194 F.3d at 195. The Courts of Appeals are divided,

however, over the status of the motive and opportunity method. In

Silicon Graphics, for example, the Ninth Circuit held that

allegations of motive and opportunity could not create a strong

inference of scienter sufficient to survive, at the pleadings

state, a motion to dismiss. Silicon Graphics, 183 F.3d at 977-79.

16

The Second and Third Circuits have held that under the PSLRA a

strong inference of scienter can be alleged by showing motive and

opportunity, or circumstantial evidence of severe recklessness or

conscious misconduct. See Advanta, 180 F.3d at 534-35; Press v.

Chemical Inv. Serv. Corp., 166 F.3d 529, 537-38 (2d Cir. 1999).9

The most sensible approach appears to us to be the one first

generally articulated by the Sixth Circuit in Comshare. The

Comshare Court held that scienter can be alleged by pleading facts

giving rise to a strong inference of recklessness or conscious

9

We do not believe that our examination of this question is to any

extent foreclosed by our opinion in Williams v. WMX Technologics, Inc.,

112 F.3d 175 (5th Cir. 1997). That was a case filed before, and not

governed by, the PSLRA, in which we held that “the amended complaint

failed to allege fraud with particularity.” Id. at 176. The only

reference to the PSLRA occurs at the end of the following paragraph,

viz:

“As the Second Circuit has noted, articulating the elements

of fraud with particularity requires a plaintiff to specify

the statements contended to be fraudulent, identify the

speaker, state when and where the statements were made, and

explain why the statements were fraudulent. Mills v. Polar

Molecular Corp., 12 F.3d 1170, 1175 (2d Cir. 1993). We agree

with the Second Circuit’s approach. This suit was the Second

Circuit’s approach. This suit was filed prior to the

effective date of the Private Securities Litigation Reform

Act, and while its provisions do not apply, the Act adopted

the same standard we apply today. See H.R. Conf. Rep. No.

369, 104th Cong., 1st Sess. 41 (1995); 15 U.S.C. § 78u-4(b).”

Id. at 177-78.

The statement that the PSLRA “adopted the same standards we apply today”

is not only mere passing dicta but, in context, clearly is directed to

the particularity requirement, with respect to specifying the allegedly

misleading statements and what is misleading about them, which the PSLRA

addresses in § 78u-4(b)(1), and not so much to the question of what

circumstances can give rise to the necessary “strong” inference of the

required state of mind as provided in § 78u-4(b)(2). The Williams

opinion discusses only the lack of particularity in the pleading, and

does not refer to motive and opportunity.

17

misconduct, but declined to hold that allegations of motive and

opportunity, “standing alone,” meet the pleading requirement. See

Comshare, 183 F.3d at 551. The Court made the entirely accurate

observation that “evidence of a defendant’s motive and opportunity

to commit securities fraud does not constitute ‘scienter’ for the

purposes of [section] 10b or Rule 10b-5 liability.” Id. Instead,

the Court stated that motive and opportunity could be “relevant” to

pleading scienter and “may, on occasion, rise to the level of

creating a strong inference of reckless or knowing conduct.” Id.

The Eleventh Circuit in Bryant noted its agreement with “the

reasoning of the Sixth Circuit” in Comshare, and went on to state

that “[w]hile allegations of motive and opportunity may be relevant

to a showing of severe recklessness, we hold that such allegations,

without more, are not sufficient to demonstrate the requisite

scienter. . . . although motive and opportunity to commit fraud may

under some circumstances contribute to an inference fo severe

recklessness, we decline to conclude that they, standing alone, are

its equivalent. . . . motive and opportunity are specific kinds of

evidence, which, along with other evidence might contribute to an

inference of recklessness or willfulness.” Bryant at 1285-86. See

also id. at 1287 (“. . . a showing of mere motive and opportunity

is insufficient to plead scienter”). In Greebel the First Circuit

stated that its “view of the” PSLRA was “close to that articulated

by the Sixth Circuit” in Comshare. Greebel at 197. The First

18

Circuit went on to say “[w]ithout adopting any pleading litany of

motive and opportunity, we reject defendants’ argument that facts

showing motive and opportunity can never be enough to permit the

drawing of a strong inference of scienter. But . . . merely

pleading motive and opportunity, regardless of the strength of the

inference to be drawn of scienter, is not enough.” Id. More

recently, the Second Circuit reached what it described as “a middle

ground” in Novak, in which it concluded that Congress’s “failure to

include language about motive and opportunity suggests that we need

not be wedded to these concepts in articulating the prevailing

standard” for demonstrating the required strong inference of

scienter. Novak at 310.

The PSLRA neither mandated nor prohibited any particular

method of establishing a strong inference of scienter. See

Greebel, 194 F.3d at 195. The statute is silent on the question.

While there was much debate in Congress over whether the PSLRA

incorporated the motive and opportunity method, the “legislative

history on this point is ambiguous and even contradictory.”

Advanta, 180 F.3d at 531. The only special standard that Congress

established was raising the pleading requirement to a “strong”

inference of scienter. See Greebel, 194 F.3d at 195-96. This

standard may only be met on the basis of “facts” which are

“state[d] with particularity” in the pleading. By otherwise

leaving open the manner in which a plaintiff may raise a strong

19

inference of scienter, and not codifying the motive and opportunity

method, Congress may be presumed to have to some extent left the

matter to the courts. See id. at 195; cf. Novak at 311 (“Although

litigants and lower courts need and should not employ or rely on

magic words such as <motive and opportunity,’ we believe that our

prior case law may be helpful in providing guidance as to how the

<strong inference’ standard may be met.”).

Therefore there is some merit in the First Circuit’s

observation that “the debate about adoption or rejection of prior

Second Circuit standards” appears to be “somewhat beside the

point.” See Greebel, 194 F.3d at 196. Motive and opportunity is

properly only an analytical device for assessing the logical

strength of the inferences arising from particularized facts pled

by a plaintiff to establish the necessary mental state. The PSLRA

requires that the necessary strong inference of scienter must arise

from “facts” stated in the complaint “with particularity” and, as

Greebel observes, “whatever the characteristic pattern of the facts

alleged, those facts must now present a strong inference of

scienter.” Id. at 196. The probative force of facts alleged

ultimately depends on reason and experience, and in this respect

guidance can properly be afforded by prior judicial decisions.

However, resolving the question of the degree of probative value to

be required also involves normative considerations. As the Second

Circuit said in Novak regarding the usual articulation of its pre-

20

PSLRA pleading standard: “this statement of the standard conceals

the complexity and uncertainty that often surround its application.

This difficulty in application stems, at least in part, from the

‘inevitable tension’ between the interests in deterring securities

fraud and deterring strike suits. . . . As a result, different

courts applying the standard to differing factual circumstances may

reach seemingly disparate results.” Id., 216 F.3d at 307.

Accordingly, we should keep in mind that the legislative history of

the PSLRA, while subject to dispute as to whether the congressional

intent it reflects was to enhance the Second Circuit’s minimum

pleading requirements, nevertheless clearly reflects congressional

intent to require no less demanding a standard. Allegations of

motive and opportunity held previously to the PSLRA to be

insufficient to allow a proper inference of scienter–see e.g.,

Novak, 216 F.3d at 307; Greebel, 194 F.3d at 198 (“mere pleading of

insider trading, without regard to either context or the strength

of the inference to be drawn, is not enough”); Melder v. Morris, 27

F.3d 1097, 1102 (5th Cir. 1994)–would presumably continue to be

insufficient. What must be alleged is not motive and opportunity

as such but particularized facts giving rise to a strong inference

of scienter. Appropriate allegations of motive and opportunity may

meaningfully enhance the strength of the inference of scienter, but

it would seem to be a rare set of circumstances indeed where those

allegations alone are both sufficiently persuasive to give rise to

21

a scienter inference of the necessary strength and yet at the same

time there is no basis for further allegations also supportive of

that inference. We conclude that simply because motive and

opportunity is alleged does not of itself automatically and

categorically mean that the necessary strong inference of scienter

is present. Whether motive and opportunity allegations will ever

alone suffice should in most cases be a moot point.

D. Pleading misrepresentations with particularity

In addition to the requirement that the plaintiff “state with

particularity facts giving rise to a strong inference” of scienter,

the PSLRA also requires the plaintiff to identify specifically the

alleged misrepresentations and/or misleading omissions:

“In any private action arising under this chapter . . .

the complaint shall specify each statement alleged to

have been misleading, the reason or reasons why the

statement is misleading, and, if an allegation regarding

the statement or omission is made on information and

belief, the complaint shall state with particularity all

facts upon which that belief is formed.” 15 U.S.C. §

78u-4(b)(2).

The effect of the PSLRA in this respect is to, at a minimum,

incorporate the standard for pleading fraud under Fed. R. Civ. P.

9(b). Greebel, 194 F.3d at 193. This statutory language appears

to comport with this Court’s relatively strict interpretation of

Rule 9(b), which requires a plaintiff “to specify the statements

contended to be fraudulent, identify the speaker, state when and

where the statements were made, and explain why the statements were

fraudulent.” Williams, 112 F.3d at 177. Again, the PSLRA provides

22

that if the complaint does not meet those requirements “the court

shall, on motion of any defendant, dismiss the complaint.” 15

U.S.C. § 78u-4(b)(3).

II. Reliance in Fraud-On-The-Market Cases

A second major question raised in this case relates to

determining the element of reliance in a section 10(b)/Rule 10b-5

claim which depends on a fraud-on-the-market theory. In the

district court’s view, many of the allegedly misleading or false

statements in question were not material and were not relied on

because this was a fraud-on-the-market case and the statements did

not have “a correspondingly favorable impact on Zonagen’s share

price.” The plaintiffs contend that the district court’s market

movement test is unsound.

Recovery of damages for false or misleading statements under

section 10(b) and Rule 10(b)(5) requires, among other things, that

the statements have been material and that the plaintiffs have

relied on them and as a proximate result suffered damage. Tuchman,

14 F.3d at 1067. As we explained in Abell v. Potomac Ins. Co., 858

F.2d 1104, 1117-18 (5th Cir. 1988), vacated on other grounds sub.

nom. Fryar v. Abell, 109 S.Ct. 3236 (1989):

“The element of reliance is the subjective counterpart to

the objective element of materiality. Whereas

materiality requires the plaintiff to demonstrate how a

‘reasonable’ investor would have viewed the defendants’

statements and omissions, reliance requires a plaintiff

to prove that it actually based its decisions upon the

defendants’ misstatements or omissions. ‘Reliance is

causa sine qua non, a type of “but for” requirement: had

23

the investor known the truth he would not have acted.’

Huddleston [v. Herman and MacLean, 640 F.2d 534 (5th Cir.

1981), rev’d in part on other grounds, 103 S.Ct. 683

(1983)] at 549 (footnote omitted). Thus,

[c]ourts sometimes consider the reliance

component of the Rule 10b-5 action to be a

part of the causation element. In this

context, the term ‘transaction causation’ is

used to describe the requirement that the

defendant’s fraud must precipitate the

investment decision. . . . On the other hand,

‘loss causation’ refers to a direct causal

link between the misstatement and the

claimant’s economic loss.”

Id. at 549 n.24 (citation omitted).10 Reliance, in other words,

generally requires that the plaintiff have known of the particular

misrepresentation complained of, have believed it to be true and

because of that knowledge and belief purchased or sold the security

in question.

However, in Basic Inc. v. Levinson, 108 S.Ct. 978 (1988), the

Supreme Court gave general approval to the “fraud-on-the-market”

theory under which reliance could be rebuttably presumed with

respect to publicly disseminated materially misleading statements

concerning companies whose shares are traded on a well-developed,

efficient market. This rested on two assumptions. First, that

10

We likewise stated in Abell that “‘The causation requirement is

satisfied in a Rule 10b-5 case only if the misrepresentation touches

upon the reasons for the investment’s decline in value.” Id. at 1117,

quoting Huddleston at 549. See also 15 U.S.C. § 78u-4(b)(4) (added by

the PSLRA):

“In any private action arising under this chapter, the

plaintiff shall have the burden of proving that the act or

omission of the defendant alleged to violate this chapter

caused the loss for which the plaintiff seeks to recover

damages.”

24

“the market price of shares traded on well-developed markets

reflects all publicly available information,” or as Basic put it in

an appended footnote, “we need only believe that market

professionals generally consider most publicly announced material

statements about companies, thereby affecting stock market prices.”

Id. at 991 & n.24. And, second, that “the reliance of individual

plaintiffs on the integrity of the market price may be presumed.”

Id. at 991. As we stated in Abell, in such a case “courts should

presume reliance . . . because most . . . investors have relied

upon the accuracy of a fraudulently distorted market price.” Id.

at 1120, citing Basic. Basic plainly states that the presumption

of reliance may be rebutted by “[a]ny showing that severs the link

between the alleged misrepresentation and . . . the price received

(or paid) by the plaintiff.” Id. at 992. This would include a

showing that “the market price would not have been affected by” the

alleged “misrepresentations,” as in such a case “the basis for

finding that the fraud had been transmitted through market price

would be gone.” Id.

In Abell we observed that Basic “essentially allows each of

the circuits room to develop its own fraud-on-the-market rules.”

Abell at 1120. We then went on to look to our prior precedent and

concluded that where there are culpable material nondisclosures

respecting shares traded on a well developed market, the plaintiff

could recover under the fraud-on-the-market theory “if he could

25

prove that the defendant’s non-disclosures materially affected the

market price of the security.” Id. at 1120-21.11 It is clear that

a fraud-on-the-market theory may not be the basis for recovery in

respect to an alleged misrepresentation which does not affect the

market price of the security in question.

The district court concluded that plaintiffs, having pled only

a fraud-on-the-market theory, could not recover as to many of the

claimed misrepresentations, including all those after April 1,

1996, respecting the Phase II trials, because the complaint

reflected that those claimed misrepresentations did not affect the

price of Zonagen shares and hence that they “were not material and

that plaintiffs did not rely on them.” The court’s discussion of

this question, however, focused almost entirely on materiality. In

this regard, the court relied principally on In re Burlington Coat

Factory Securities Litigation, 114 F.3d 1410 (3d Cir. 1997).

There, the Third Circuit observed that the fraud-on-the-market

theory, on which that suit was grounded, “accords . . . a

rebuttable presumption of reliance if plaintiffs bought or sold

their securities in an efficient market,” “the presumption of

reliance [being] based on the theory that in an efficient market

the misinformation directly affects the stock prices at which the

11

Abell ultimately held that the fraud-on-the-market theory was

unavailable there because the securities at issue were not traded on an

efficient market. Id. at 1122. We hence required proof of actual,

individual reliance. Id. at 1123.

26

investor trades and thus, through the inflated or deflated price,

causes injury even in the absence of direct reliance.” Id. at 1419

n.8 (citing Basic).12 The court then held that because the

corporation’s July 29, 1994, disclosure of disappointing sales

information had “no appreciable effect on the market price” of its

stock, the annual report’s failure to disclosure the same

information was immaterial and hence not actionable. Id. at 1425.

The court explained as follows:

“In the context of an ‘efficient’ market, the concept of

materiality translates into information that alters the

price of the firm’s stock. Cf. Shaw [v. Digital

Equipment, 82 F.3d 1194 (1st Cir. 1996)], 82 F.3d at 1218

(in cases involving the fraud on the market theory of

liability, statements identified as actionably misleading

are alleged to have caused injury, ‘not through the

plaintiffs’ direct reliance upon them, but by dint of the

statements’ inflating effect on the price of the security

purchased’) (emphasis added) . . .”13

While we agree with Burlington and the district court as to

the requirement, in cases depending on the fraud-on-the-market

theory, that the complained of misrepresentation or omission have

actually affected the market price of the stock, we conclude that

12

Burlington goes on to state: “. . . in order to avail themselves

of the fraud on the market theory and the benefit of not having to plead

specific reliance on the alleged misstatement or omission, plaintiffs

have to allege that the stock in question traded on an open and

efficient market.” Id.

13

More recently, the Third Circuit reiterated and again applied

this aspect of its Burlington materiality holding in Oran v. Stafford,

226 F.3d 275 at 282-83 (3d Cir. 2000), a Rule 10(b)(5) class action

(which, being a class action, necessarily depended on the fraud-on-the-

market theory, see Basic, 108 S.Ct. at 989).

27

it is more appropriate in such cases to relate this requirement to

reliance rather than to materiality. That is how both Basic and

Abell approach the matter. We also agree with Burlington and the

district court that although there is generally a presumption that

potentially significant publicly disseminated information is

reflected in the price of stock traded on an efficient market, the

presumption is rebuttable, and where the facts properly considered

by the district court reflect that the information in question did

not affect the price of the stock then the district court may

properly deny fraud-on-the-market based recovery.

III. Phase II trials

The complaint proceeds on the basis of a fraud-on-the-market

theory. It alleges:

“104. At all relevant times, the market for Zonagen

common stock was an efficient market for the following

reasons, among others:

a) At all relevant times during the Class

Period, Zonagen’s common stock was listed and

actively traded on the NASDAQ Small Cap

Market, a highly efficient market, . . .

b) As a registered and regulated issuer of

securities, Zonagen filed periodic reports

with the SEC, in addition to the frequent

voluntary dissemination of information

described in this Complaint;

c) Several financial analysts covered and

reported on Zonagen’s developments, including

analysts with Harris Webb & Garrison, Moody’s,

Volpe Brown Whelan & Co., Asensio & Co., and

Raymond James & Associates.

105. As a result of the above, the market for Zonagen

securities promptly digested current information with

respect to Zonagen from all publicly available sources

and reflected such information in Zonagen’s stock prices.

Under these circumstances, all purchasers of Zonagen

28

stock during the Class Period suffered similar injury

through their purchase of securities at prices which were

artificially inflated by the Defendants’ manipulative

activities. Thus, a presumption of reliance applies.”

The complaint also includes a graph showing the daily trading

volume, and the high ask, low bid and closing price of Zonagen

shares from February 7, 1996, through the close of the class

period. The price per share rose from $12 3/8 on February 7, 1996,

to $16 on March 13, 1996, and this price movement is circled on the

graph and is accompanied by a notation there stating “Defendants’

misrepresentations concerning the Phase II trial results

artificially inflate ZONA’s share price.” The complaint elsewhere

also specifically alleges concerning the statements made February

7 and 14, and March 5 and 14, 1996, that “[t]he Defendants’ false

and misleading statements concerning the results of the Phase II

trials had the intended effect: Zonagen’s share prices climbed from

$12 3/8 on February 7, 1996 to $16 on March 13, 1996.” The price

per share also rose from 17 3/8 on May 23, 1997 to 24 ½ on May 27,

1997 and thereafter to 32 1/4 on July 18, 1997, and ultimately to

a class period high of 44 3/8 on October 13, 1997, and this price

movement is also circled on the graph and is accompanied by a

notation there stating “Defendants issue a series of

misrepresentations concerning the efficacy of Vasomax and the

company’s intellectual property rights to Vasomax.” The price per

share fell from approximately $40 November 17, 1997 to close at 13

15/16 on January 12, 1998, the first trading day following the end

29

of the class period, and this price movement is likewise circled on

the graph and is accompanied by a notation there that “the market

digests Asensio’s revelations,” obviously referring to the

Complaint’s allegations concerning a “strong sell” recommendation

for Zonagen stock and accompanying report issued November 18, 1997

by Asensio & Co., an institutional investment banking company, and

a similar Asensio report issued January 9, 1998. These are the

only indications on the graph of any effect of any public

disclosures on the price of Zonagen stock. Apart from the graph,

the Complaint also elsewhere alleges that as a result of the

November 18, 1997 and January 9, 1998 Asensio reports “Zonagen’s

share prices tumbled, falling from a class period high of 44 3/8 on

October 13, 1997 to a low of 13 1/4 on January 12, 1998,” and that:

“Following the announcements in which the Defendants

misrepresented and omitted material facts concerning the

Phase III clinical trials for Vasomax and the results of

those trials, Zonagen’s share prices responded highly

favorably, closing at $24 ½ on May 27, 1997 (the day of

the first announcement of the Phase III results), up from

$17 3/8 on May 23, 1997 (the last trading day before the

announcement). On July 18, 1997, after no further

material news announcements, the Company’s shares closed

at $32 1/4.”

These are the only allegations in the Complaint as to the

affect on Zonagen share prices during the class period of any one

or more particular alleged misrepresentations by defendants.14

14

The Complaint’s allegations as to the affect of publicly

disclosed information on Zonagen share prices after the class period are

only the following: that the March 27, 1998 announcement that the FDA

had approved Pfizer’s Viagra for prescription sales “caused . . .

30

The district court concluded that the allegedly misleading

statements concerning the Phase II trials made by defendants in

May, June, July and on August 2, 1996 were not material and were

not relied on by plaintiffs because the Complaint reflects that

“throughout May, June, July and August of 1996 Zonagen’s share

price did not rise, but instead fell steadily until reaching an

all-time low of less than $10 per share in early August” and

“plaintiffs fail to allege” that these “statements had a

correspondingly favorable impact on Zonagen’s share price,” and

“because plaintiffs’ complaint demonstrates that these statements

did not have a favorable effect on Zonagen’s share prices.” We

agree with the district court, particularly as to the May 9 and 16,

1996, statements, the first strongly implying and the latter

expressly stating that the Phase II results were statistically

[Zonagen’s] share prices to rise temporarily . . . simply [as] a

reaction to the media sensation surrounding the approval of Viagra,”

and, that as a result of adverse public reports by analysts in early

June 1998 “Zonagen’s share prices tumbled again, falling from 36 3/4 on

June 2, 1998 to 24 3/4 on June 12, 1998.”

As previously observed, the Complaint and its attachments reflect

that the average closing price for Zonagen shares during the 90 days

following the end of the class period (January 9 through April 10, 1998)

was $20 1/5. It likewise appears that prior to April 10, 1997, the

stock had never traded as high as $20 a share, and that it never traded

that high during the portion of January 1998 prior to the close of the

class period. Cf. 15 U.S.C. § 78u-4(e)(1) (added by the PSLRA) (damages

may not exceed difference between plaintiff’s purchase (or, where

appropriate, sale) price and the mean trading price during the 90 day

period beginning on the date information correcting the complained of

misstatement or omission is disseminated to the market).

31

significant.15 The Complaint alleged that on November 14, 1996,

Zonagen filed its Form S-3 with the SEC which stated that:

“. . . while Phase II clinical trial provided the Company

with what is expected to be the optimum dose for future

development, it did not provide the Company with the

necessary p-value required to prove statistical

significance. There can be no assurance that VASOMAX

(TM) will prove to be safe or effective at the current

dose to be tested, or that VASOMAX (TM) will be approved

by the FDA for any indication.”16

So far as the Complaint reflects, at no time subsequent to May

16, 1996, were there any statements to the effect that the Phase II

trials produced statistically significant results or data. There

is no allegation in the Complaint that the November 14, 1996, S-3

filing resulted in any decrease in the price of Zonagen stock, and

the graph in the Complaint indicates that it did not. The district

court noted that the stock “climbed steadily from below $10 per

share in late December 1996 to approximately $18 per share on March

15

As to the other statements during this period (through early

August 1996) respecting the Phase II trials, we conclude that in any

event the particulars in which these statements were false or misleading

were not adequately pled, that otherwise the statements were at most

mere optimistic generalizations consisting of “the type of ‘puffing’

that . . . [the] circuits have consistently held to be inactionable,”

Lasker v. New York State Elec. & Gas Corp., 85 F.3d 55, 59 (2d Cir.

1996), and that circumstances giving rise to the requisite “strong

inference” of scienter in respect to those statements concerning the

Phase II trials were not pled. We also so conclude with respect to the

statements concerning the Phase II trials in the March 31, 1997 Form 10-

K (the only other complained of statement concerning the Phase II

trials), filed well after the November 14, 1996 Form S-3 disclosed that

the Phase II trials results were not statistically significant.

16

This statement was in the text on the fifth page of the 20 page

(exclusive of exhibits) Form S-3 and appeared as a part of the slightly

less than one page discussion under (and on the same page as) the all

capitalized heading “Uncertainties Related To Clinical Trial Results.”

32

18, 1997.” Plaintiffs do not challenge these calculations or

contend that the November 14, 1996 S-3--with its express disclosure

that the Phase II trials did not produce statistically significant

results–adversely affected the price of Zonagen shares.17

Given that Zonagen shares did not rise, but rather declined,

throughout the same five months following the May 9 and 16, 1996,

press releases indicating and stating that the Phase II trial

results were statistically significant, and did not further

decline, but rather rose throughout the several months following

the November 1996 SEC filing disclosing that those trials did not

have statistical significance, and since there is no allegation

either explaining this or asserting that those May 1996

representations were ever repeated or that they affected the price

of Zonagen stock, we conclude that the district court properly

17

It appears that Zonagen stock closed at or above $12 3/8 from

January 26, 1996 through February 7, 1996, the first day of the class

period, when it also closed at $12 3/8. The highest close between

February 7 and March 15, 1996 was $17 1/4 on March 5, 1996. It closed

at $16 on March 13, at $13 3/8 on March 14, and at $12 3/8 on March 15,

1996. After March 15, 1996, the stock steadily declined and did not

again close as high as $12 3/8 until January 15, 1997, when it closed

at $12 ½. On May 8, 1996, the day before the May 9, 1996, press

release, the stock closed at $10 ½ and never again closed higher than

that until December 2, 1996, when it closed at $11 ½.

The SEC Form S-3 was filed November 14, 1996. On November 12, 13,

and 14, 1996, the stock closed at $9 1/4; on November 15 through 22 it

closed at $8 7/8, and the next two trading days at $9 and $8 3/4;

thereafter and through December 10, 1996, it closed at or above $9 1/4;

from December 11 through December 20, 1996, the closing price ranged

from $8 7/8 on December 11 and 13 to a low of $8 1/8 on December 18,

rising again to $9 1/8 on December 20, 1996. Thereafter and through the

filing of the complaint, the stock has always closed above $9 1/4;

indeed has always closed above $13 3/4 since January 1997.

33

determined that those May 9 and 16, 1996, representations were not

actionable under a fraud-on-the-market theory.

Plaintiffs argue that the district court erroneously required

that the statements be “followed by an immediate rise in share

prices.” We reject this contention. Five months is considerably

more than “immediate.” Further, there was no decline following the

November 1996 SEC Form S-3 filing. Moreover, plaintiffs pleaded

that the “market . . . promptly digested current information with

respect to Zonagen from all publicly available sources and

reflected such information in Zonagen’s stock prices” (emphasis

added). Plaintiffs also argue that the district court’s holding is

in conflict with our decision in Abell because there we held that

the fact that there was no significant adverse affect on price when

the facts concealed on the initial offering were disclosed two or

three years later did not preclude a finding that the non-

disclosure was material as respects the initial offering. Id., 858

F.2d at 1116-17. However, Abell was not a fraud-on-the-market

case, for we there held that the market was not a sufficiently

efficient one for that purpose, and hence we required proof of

actual reliance by the specific individual plaintiffs. Id. at

1119-23. We are not here addressing materiality, certainly not in

a case not based on the fraud-on-the-market theory; we are only

addressing reliance in a case resting on the fraud-on-the-market

34

theory, and we do not otherwise address reliance.18 Materiality is

determined by evaluating whether there is “[a] substantial

likelihood that” the false or misleading statement “would have been

viewed by the reasonable investor as having altered the ‘total mix’

of information made available.” Basic, 108 S.Ct. at 983.

Materiality thus looks to likely potential. Reliance, on the other

hand, ultimately looks to what actually happened. Abell, 858 F.2d

at 1118. If the market price was not actually affected by the

statement, reliance on the market price does not of itself become

reliance on the statement. We also realize that in certain special

circumstances public statements falsely stating information which

is important to the value of a company’s stock traded on an

efficient market may affect the price of the stock even though the

stock’s market price does not soon thereafter change. For example,

if the market believes the company will earn $1.00 per share and

this belief is reflected in the share price, then the share price

may well not change when the company reports that it has indeed

18

Similarly, inapposite is our decision in Justin Industries, Inc.

v. Choctaw Sec., L.P., 920 F.2d 262, 268 n.6 (5th Cir. 1990). Justin

was speaking to materiality, not reliance, and it was not a fraud-on-

the-market case. Moreover, it dealt with proxy solicitation where the

test for materiality is not the likely potential for affect on the

market price but rather whether “there is a substantial likelihood that

a reasonable shareholder would consider it important in deciding how to

vote.” TSC Industries, Inc. v. Northway, Inc., 96 S.Ct. 2126, 2132

(1976) (emphasis added). See also Johnson v. Sawyer, 47 F.3d 716, 737

n.44 (5th Cir. 1995) (en banc) (information as to director’s prior

conviction must be included in proxy statement if it is material to an

evaluation of his integrity, even if not material to deciding whether

to invest in the company).

35

earned $1.00 a share even though the report is false in that the

company has actually lost money (presumably when that loss is

disclosed the share price will fall). However, no such special

circumstance is alleged or even hinted at here. Moreover, here,

after the May 9 and 16, 1996, press releases stating (or clearly

implying) that the Phase II trial results were statistically

significant, the stock’s price fell to only slightly over half its

price just before the statements were made and likewise

significantly below its price at the opening of the class period;

and after the November 14, 1996 Form S-3 reflected that the Phase

II results were not statistically significant, the price of the

stock rose and after December 20, 1996 never again during the class

period or prior to the filing of the complaint closed as low as

what it had closed at on each of the three days just prior to the

filing of the S-3.

The district court did not err in holding that the complaint’s

allegations as to statements concerning the Phase II trials were

insufficient.

IV. Phase III Trials and the “Improved Formulation” of Vasomax

The complaint alleges that the Phase III trials were

“materially flawed” such that their reported positive results were

unreliable. These alleged flaws included faulty randomization of

participants, pre-screening participants to exclude those suffering

from side-effects, conflicts of interest in those operating the

36

test centers, and the existence of severe side effects. The

allegations about the Phase III statements suffer from a lack of

required specificity, either in pin-pointing the particular

misleading statement (other than general statements that the Phase

III results were “positive”) or identifying with any degree of

detail how these shortcomings impacted the trials. Moreover, it is

well-established that generalized positive statements about a

company’s progress are not a basis for liability. See Lasker v.

New York Elec. & Gas. Corp., 85 F.3d 55, 59 (2d Cir. 1996)

(observing that “broad, general statements” are “precisely the type

of <puffery’ that this and other circuits have consistently held to

be inactionable”).

Similarly, the plaintiffs’ allegations regarding statements by

the defendants that Vasomax was a “fast-acting,” “improved

formulation” for delivering phentolamine fail because they identify

nothing more than inactionable “puffing.” Even though Vasomax’s

potential commercial viability is material, these statements are

little more than optimistic generalizations, and therefore cannot

support the plaintiffs’ claim. See Lasker, 85 F.3d at 59.

Moreover, the “facts” pled “with particularity” are inadequate to

give rise to the necessary “strong inference” of scienter with respect

to the statements concerning the Phase III trials. Under the PSLRA it

is clear that conclusory allegations of state of mind do not suffice for

this purpose, as we have indeed held in cases governed by pre-PSLRA law.

37

See, e.g., Lovelace v. Software Spectrum Inc., 78 F.3d 1015, 1019 (5th

Cir. 1996); Melder, 27 F.3d at 1104; Tuchman, 14 F.3d at 1069.

Moreover, “where a company accurately reports the results of a

scientific study, it is under no obligation to second-guess the

methodology of that study. Medical researchers may well differ with

respect to what constitutes acceptable testing procedures, as well as

how best to interpret data garnered under various protocols.” Padnes

v. Scios Nova Inc., 1996 WL 539711 at *5 (N.D. Cal. 1996). See also In

Re Medimmune, Inc. Securities Litigation, 873 F. Supp. 953, 966 (D. Md.

1995) (same); In Re Biogen Securition, 179 F.R.D. 25, 38 (D. Mass. 1997)

(citing Padnes and Medimmune with approval in this respect).

The instant allegations of motive and opportunity are likewise

insufficient. We agree with the district court that the allegations

that corporate officers and directors would benefit from enhancing the

value of their stock and/or stock options and that the corporation would

benefit by receiving more for its shares to be issued in the July 1997

public offering are likewise insufficient to support a strong inference

of scienter. We so held in the pre-PSLRA decisions in Melder, 27 F.3d

at 1102 (alleged inflation of stock price to “successfully bring to

fruition the [public] offerings” and to “enhance the value of . . .

[officer or director] holdings and options”) and Tuchman, 14 F.3d at

1068-69. See also Acito v. Imcera Group Inc., 47 F.3d 47 at 54 (5th

Cir. 1995).

The only allegation of officer or director trading is that Blasnik,

38

an outside director, sold 62,000 shares on April 25, 1996, at $9.94 a

share and 80,000 shares between January 31, 1997, and February 3, 1997,

at prices between $16.03 and $16.25 a share. We agree with the district

court that these allegations are insufficient. The total sales amounted

to about 18.5% of the shares attributable to Blasnik. As to the April

25, 1996, sale, it took place more than a month after the stock began

its mid-March 1996 several month steady decline, was at a price well

below that at the beginning and at the end of the class period, and is

less than a third of what the shares were traded for in the July 1997

public offering and less than a fourth of the October 1997 high. As to

the sales between January 31, 1997, and February 3, 1997, we note, as

did the district court, that they “took place long after the

dissemination of the definitive Phase II results in the S-3 filed on

November 13, 1996, and long before the announcement of the preliminary

results from the Phase III trials on May 27, 1997,” that plaintiffs “do

not allege . . . any false and/or misleading statements between November

15, 1996 and March 31, 1997,” and that the sales were at “only about

half the price to which plaintiffs allege defendants inflated the market

based on misrepresentation of the Phase III results in May, June and

July of 1997.” As the district court correctly observed, “[a]t most

plaintiffs allege that one outside director sold a fraction of his

holdings at times that were unrelated to any Company announcements and

at prices that were far below that which he could have obtained by

39

selling a few weeks earlier or later.”19 This does not suffice.

“Insider” trading must be “unusual” to have meaningful probative value.

Acito, 47 F.3d at 54. Sales such as Blasnik’s which are “so

inauspiciously timed” do not meet this test. In Re Apple Computer

Securities Litigation, 886 F.2d 1109, 1118 (9th Cir. 1989). Moreover,

“[t]he fact that the other defendants did not sell their shares during

the relevant class period undermines plaintiffs’ claim.” Acito, 47 F.3d

at 54; San Leandro Emergency Medical Plan v. Philip Morris, 75 F.3d 801,

814 (2d Cir. 1996). This is particularly so given Blasnik’s status as

an outside director and the absence of any allegation of sale by any

officer or by any other director.

The district court did not err in holding that the allegations

concerning the Phase III trials were insufficient.

V. Zonagen’s “discovery” of Immumax

Plaintiffs allege that defendants misrepresented that the company

had “discovered” a “new adjuvant” called Immumax. The representations

in question appear in the April 1, 1996 10K (and are repeated in the May

19

We note there is no allegation that Blasnik sold at a profit.

Plaintiffs have stated both below and on this appeal that the sales by

Blasnik were “through his affiliate, Petrus fund.” We note that the

Zonagen May 14, 1996 proxy statement filed with the SEC reflects that

all but 10,000 of the 845,793 shares attributable to Blasnik were

attributable to him “by virtue of his affiliation with Petrus Fund,

L.P.,” and that “Mr. Blasnik disclaims beneficial ownership of the

shares owned by Petrus Fund, L.P.” The May 14, 1997, proxy statement

filed with the SEC likewise reflects that all but 12,500 of the 768,293

shares attributable to Blasnik were attributable to him “by virtue of

his affiliation with Petrus Fund, L.P.” and that “Mr. Blasnik disclaims

beneficial ownership of the shares owned by Petrus Fund, L.P.”

40

20, 1996 amended 10K), and in the November 14, 1996 S-3, the March 31,

1997 10K, the June 1, 1997 S-3, and the July 22, 1997 Form 424B

prospectus. The plaintiffs contend that the statements are false

because Dr. Balbir Bhogal, Zonagen’s former Director of Immunology, told

Podolski before the statements were made that Immumax was not a new

adjuvant but rather the same compound of a previously patented product

known as Chitosan.

The documents in question all state, at most, that the “Company

believes that it has discovered a new adjuvant” which it named Immumax

and for which it had applied for a patent in September 1994. None of

the documents state that any favorable action had been taken on the

patent application or that any product development efforts had been

undertaken or planned respecting Immumax. The April 1, 1996 10K also

refers to Immumax as a “unique naturally occurring substance which

enhances the immune response against weakly immunogenic materials.” The

November 14, 1996 S-3 additionally states as follows:

“EARLY STATE OF PRODUCT DEVELOPMENT

The Company has not completed the development of any

proprietary product, and all of the Company’s revenues

currently are derived from sales by FTI of products developed

or manufactured by others. The development or acquisition

of commercially viable products will require significant

further investment, research, development, pre-clinical and

clinical testing and regulatory approvals, both foreign and

domestic. There can be no assurance that the Company will

be able to produce at reasonable cost, or market

successfully, any such product. Products, if any, resulting

from the Company’s research and development programs are not

expected to be commercially available for several years.

Moreover, although the Company has in the past and will

continue to seek opportunities for the licensing of existing

41

product lines in the field of human reproductive healthcare,

there can be no assurance that the Company will be able to

successfully or profitably market its current or future

products under development.

SUBSTANTIAL DEPENDENCE ON ONE PRODUCT

Substantially all of the Company’s efforts and

expenditures over the next few years will be devoted to

VASOMAX (TM). Accordingly, the Company’s future prospects

are substantially dependent on favorable results of the

proposed Phase III clinical trials, approval by the FDA and

the successful commercialization of VASOMAX (TM).”

Substantially the same language appears in the March 31, 1997 10K, the

June 11, 1997 S-3 and the July 22, 1997 Form 424B.20 We conclude that

there is no “substantial likelihood” that a reasonable investor would

consider these statements about a believed discovery whose value was

wholly speculative to have “significantly altered the ‘total mix’ of

information” about Zonagen, Basic, 108 S.Ct. at 983, and that these

statements respecting Immumax were hence immaterial as a matter of law.

The district court did not err in holding that the Immumax

allegations were insufficient.

VI. The Zorgniotti patent for Vasomax

Plaintiffs also allege that defendants made misleading statements

concerning what is referred to as the Zorgniotti patent and its

application to Vasomax. The rights to this patent application were

20

While the April 1, 1996 10K did not include similar express

substantial dependence on one product language, such dependence on

Vasomax appears evident from the document as a whole. Moreover, as to

the April 1, 1996 10K, Zonagen share prices thereafter steadily declined

for many months, and did not further decline, but rather rose, following

the November 1996 S-3.

42

acquired by Zonagen in April 1994, the patent was approved in June 1996

and was formally issued October 15, 1996.

The essence of plaintiffs’ claim is that the Zorgniotti patent did

not cover Vasomax because it was only a method of use patent covering,

inter alia, phentolamine tablets or other items dissolved in the mouth

but excluding those swallowed and dissolved in the stomach,21 and that

Vasomax was at all times intended to be administered only as a pill to

be swallowed, and was hence affirmatively excluded from the patent so

21

The patent commences by stating that it is “directed to improved

methods for modulating the human sexual response by administering

vasodilator agents to the circulation of a human via transmucosal,

transdermal, intranasal or rectal routes of administration that obviate

‘first pass’ deleterious effects on such agents.” The application

subsequently states “when an orally ingested drug reaches the intestine,

it is absorbed into the portal circulation and delivered to the liver

where it can be metabolized and inactivated. Hepatic inactivation

following absorption of a drug from the gastrointestinal tract is

referred to as ‘first pass’ effect . . . and, along with poor absorption

and slow transit times through the gastrointestinal tract, functions to

require larger oral doses of drugs than may be necessary with other

routes of administration. This, in turn, can account for delays in the

onset of the therapeutic effect of a drug.” Later, the patent states

that “[f]or purposes of the present invention, ‘transmucosal delivery’

generally refers to delivery of the drug to the oral or pharyngeal

mucosa and includes buccal delivery, sublingual delivery, and delivery

to the pharyngeal mucosa, but not to the stomach” (emphasis added). It

gives as an example of a delivery covered by the patent “[v]asoactive

agents . . . combined in a hard candy (which may be dissolved in the

mouth) or in chewing gum to provide buccal or sublingual delivery to the

oral mucosa.” The patent also states that “[v]asodilating agents useful

in the present invention include, but are not limited to, the group

consisting of phentolamine mesylate, phentolamine hydrochloride . . .

The presently preferred agent is phentolomine mesylate. The presently

preferred administrative route is transmucosal, especially buccal.”

Vasomax uses phentolomine mesylate as the active pharmacologic

agent.

“Buccal” has been defined as “directed toward the cheek;” “of,

relating to, involving, or lying within the mouth,” “:ORAL.” Websters

Third New International Dictionary (1981) at 287.

43

that “Vasomax was not covered or protected in any manner by this

patent.”

The principle basis for plaintiffs’ claim in this respect is

Zonagen’s June 24, 1996 press release stating, as alleged in paragraph

47 of the complaint, as follows:

“47. On June 24, 1996, the Defendants issued a press

release, stating, inter alia:

Zonagen, Inc. announced today that it has received

notification from the United States Patent and Trademark

Office that the patent covering its use of VASOMAX (TM) as

a treatment for erectile dysfunction (impotency) has been

allowed.

The Company noted the approval was granted for the first of

two separate applications associated with VASOMAX (TM). The

second, more recent application is still pending.

‘The approval of our U.S. patent, the VASOMAX (TM) IND

submission and the selection of our Phase III development

team are crucial events in our commercialization strategy,’

declared Joseph S. Podolski, President and CEO, Zonagen, Inc.

. . .

(Emphases added).”

If, as plaintiffs have alleged, Vasomax was at all times intended

to be administered only as a pill or tablet to be swallowed and

dissolved in the stomach, then it was plainly not covered by the

Zorgniotti method of use patent which clearly and affirmatively excluded

that method of use. It was hence false and misleading for the June 24,

1996 press release to state that “Zonagen, Inc. announced . . . that the

patent covering its use of Vasomax (TM) as a treatment for erectile

dysfunction (impotency) has been allowed” (emphasis added). The patent

did not “cover” Zonagen’s use of Vasomax, but rather affirmatively

44

excluded that use.22

Plaintiffs also complain of subsequent Zonagen statements

concerning the Zorgniotti patent, namely statements in its November 14,

1996 S-3, March 31, 1997 10K, June 11, 1997 S-3 and July 22, 1997 Form

424B prospectus.23 Considered individually, none of these statements can

of themselves reasonably be considered false or misleading in the same

22

We are somewhat concerned that the language from the June 24,

1996 press release as quoted in the complaint differs from the language

in the purported copy of the same press release attached (along with

numerous other documents) to defendants’ motion to dismiss (all such

documents being covered by the single affidavit of an attorney with the

firm representing the defendants in this litigation that they are true

and correct copies). The copy attached to the motion to dismiss states

in relevant part that “Zonagen, Inc. announced . . . that the patent

covering the use of Vasomax (TM) as a treatment for erectile dysfunction

(impotency) has been allowed” (emphasis added). The difference is that

as quoted in the complaint the press release refers to “its” –

necessarily Zonagen’s – “use,” while according to the copy attached to

the motion to dismiss, the press release refers to “the use”–not “its

use.” The district court did not address this discrepancy, nor has it

been addressed in this appeal by any of the parties, and the press

release is not a document filed with any governmental agency a certified

copy of which we could procure; plaintiffs in their brief on appeal

continue to quote the language of the press release as set out in the

complaint, and defendants in their brief have not asserted that this is

not the language used in the press release. We have accordingly

proceeded on the assumption that the complaint accurately quotes the

language of the press release. The district court on remand should

resolve the discrepancy–which conceivably could be relevant to the

issues of falsity and scienter–and likewise consider whether any

sanctions are called for.

23

The complaint additionally cites the April 1, 1996 10K which

refers to the Zorgniotti “patent application” as being “for the use of

phentolamine meyslate (“Phentolamine”) as an ‘on demand’ oral treatment

for male impotency,” and in a subsequent paragraph states that “Vasomax

uses phentolamine as the active pharmacologic agent.” No allegations

reflect that either statement is false or misleading, and the statements

appear to be correct.

45

manner as the June 24, 1996 press release.24 However, the statements

cannot be considered by themselves, for the statements in the above

referenced June 24, 1996 press release–that the patent covered Zonagen’s

use of Vasomax–had never been retracted or modified and it had not been

disclosed that the Zorgniotti patent did not cover Zonagen’s use of

Vasomax or did not extend to pills or tablets to be swallowed and

dissolved in the stomach as Vasomax was. Hence, in the absence of other

factors, a fact finder could determine that readers of these later

statements could reasonably be assumed to have understood them as

referring to the patent as described in the June 24, 1996 press

releases, so that the representation of that press release was in effect

carried forward to March, June and July 1997.25

24

The November 14, 1996 S3 and the March 31, 1997 10K merely refer

to the Zorgniotti patent as one “with respect to its [Zonagen’s] male

impotency technology (Vasomax (TM));” the June 11, 1997 S-3 and the July

22, 1997 Form 424B merely refer to the patent as “relating to Vasomax.”

The June 11, 1997 S-3 and the July 22, 1997 Form 424B likewise expressly

state that the Zorgniotti patent “is a method-of-use patent that covers

only the use of certain compounds to treat specified conditions, rather

than a composition-of-matter patent which would cover the chemical

composition of the active ingredient.” Essentially the same statement

is made in the March 31, 1997 10K.

25

Plaintiffs also complain of the statement in the November 6, 1996

Zonagen press release that “Zonagen has received a domestic patent and

has filed international patent applications on the Vasomax formulation,”

which they allege falsely states that the Zorgniotti patent (the only

domestic patent Zonagen then had) is a composition-of-matter patent.

However, in the March 31, 1997 10K, the June 11, 1997 S-3 and the July

22, 1997 Form 424B it was clearly stated that the patent was only a

method-of-use patent and was not a composition-of-matter patent. The

stock price did not appreciably rise between November 6, 1996 and March

31, 1997, and did not fall, but rather significantly rose, after March

31, June 11 and July 22, 1997, and nothing in the complaint asserts or

suggests any explanation for this other than the fact that the November

6, 1996 press release did not affect the price of the stock. Hence,

46

The district court held that scienter was not adequately pled as

to the Zorgniotti patent statements made in 1997, but it considered

those statements in isolation and not in light of the never retracted

assertions of the June 24, 1996 press release. Although the question

is a close one, we conclude that the necessary strong inference of

scienter is pled as to Podolski, who was, and had been since July 1992,

President and Chief Executive Officer, as well as a director, of the

corporation.26 We recognize that normally an officer’s position with a

company does not suffice to create an inference of scienter. Melder,

27 F.3d at 1103. See also Advanta, 180 F.3d at 539. However, there are

a number of special circumstances here which, taken together, suffice

to support a different result in the present case. To begin with,

Zonagen was essentially a one product company, and that product was

Vasomax. Thus, the November 1996 S-3, as well as the March 31, 1997

10K, the June 11, 1997 S-3, and the July 22, 1997 Form 424B, all reflect

that “[s]ubstantially all of the Company’s efforts and expenditures over

the next few years will be devoted to Vasomax (TM)”, and that “the

fraud-on-the-market “reliance” is lacking as to this alleged

misstatement.

26

The June 11, 1997 Form S-3 also reflects that Podolski had joined

Zonagen in 1989 as Vice President of Operations. In the 12 years

preceding 1989, he had held engineering, product development and

manufacturing positions with Monsanto Company, and before that had spent

eight years at Abbott Laboratories, Dearborn Chemical Company and Baxter

Pharmaceuticals in development of fine chemicals, antibiotics,

pharmaceuticals and hospital products.

Proxy statements filed during the class period reflect that he held

a bachelor’s degree in chemistry and a master’s in chemical engineering.

47

Company’s future prospects are substantially dependent on” Vasomax. See

Advanta, 180 F.3d at 539 (citing case in which scienter inference

adequately supported by fact that the contract in question “‘was

undeniably the most significant contract’” in the company’s history).

Further, patent protection for Vasomax was obviously important. The

June 11, 1997 S-3 states that “[t]he Company’s ability to compete

effectively with other companies is materially dependent on the

proprietary nature of the Company’s patents and technologies,” and in

the June 24, 1996 press release Podolski is quoted as describing the

approval of the Zorgniotti patent as a “crucial event[s].”27

Additionally, the Company had acquired the Zorgniotti patent application

in April 1994, so there was ample opportunity to become familiar with

it prior to June 1996. In this connection, we also note that the

Company is not large. As reflected by its 10K’s filed April 1, 1996 and

March 31, 19979, the Company had only thirty-two full time employees in

January 1996 and only thirty-five in January 1997. Finally, the

Company’s June 24, 1996 and November 6, 1996 press releases, which

describe the Zorgniotti patent, both quote Podolski, and an article in

the issue of Fortune distributed in mid-February 1998, states: “[i]n a

27

The Zorgniotti patent was the Company’s only patent approved or

issued during the class period which was claimed to relate to Vasomax.

There was another patent application (the Lowrey patent) pending during

the class period but it was not granted until March 25, 1998 (it was

both a formulation and a method-of-use patent). Indeed, as Zonagen

reported in its November 1996 S-3, the Lowrey patent had been rejected

in a non-final first office action by the United States Patent and

Trademark Office. The Company’s subsequent class period filings all

state there was no assurance the Lowrey patent would be granted.

48

recent interview, Podolski concedes, ‘You can say today no patent

specifically covers Vasomax;’ he claims the company’s issued patent

‘broadly covers’ the drug.”

Taking all the above factors together we conclude that they

suffice, if perhaps only barely so, to support the necessary “strong

inference” of scienter on the part of Podolski and Zonagen with respect

to the statement that the Zorgniotti patent covers Zonagen’s use of

Vasomax.28 The result, however, is otherwise as to Blasnik and Sutter,

both of whom were outside directors, neither of whom is alleged to have

made any statements or issued any press release about any patent (or

Vasomax itself), and as to neither of whom is any other allegation made

tending to support an inference of scienter in this respect. As

previously noted, the stock sales attributable to Blasnik are wholly

insufficient for this purpose.29

28

Nothing in our opinion on this issue should be read as precluding

pre-trial judgment against the plaintiffs in the event of fuller

development of contextual facts. For example, our conclusion on this

issue is made in the context of the allegation that Vasomax was always

intended only as a pill or tablet to be swallowed and dissolved in the

stomach. Should this not be the case and should Vasomax have been

intended also (or alternatively) to be administered in a way compatible

with the Zorgniotti patent–such as being dissolved in the mouth–or if

it was believed by Zonagen to be readily adaptable to that method of

administration, then a different question would be presented. See also

note 22, supra.

29

Because the district court ruled that no violation of § 10(b) had

been adequately pled as to Zonagen (or any other party), it further

ruled that accordingly there could be no secondary liability of any of

the individual defendants as “controlling persons” of Zonagen under §

20(b) of the Exchange Act, 15 U.S.C. § 78+(a). See Shields v. Cityhurst

Bancorp, Inc., 25 F.3d 1124, 1132 (2d Cir. 1994). However, we have held

that the complaint adequately pleads § 10(b) liability as to Zonagen

49

Conclusion

We have held that with one exception the district court did not err

in holding that the allegations of the complaint were insufficient.

However, we have also held that the district court did err in

holding insufficient the allegations of the complaint with respect to

Zonagen having stated that the Zorgniotti patent covered Zonagen’s use

of Vasomax, so far as concerns Zonagen and Podolski, and in failing to

address the potential section 20(a) liability of Blasnik and Sutter in

that particular respect.30

We accordingly vacate the district court’s judgment of dismissal

and remand for further proceedings not inconsistent herewith.

VACATED and REMANDED

(and Podolski) with respect to the statement that the Zorgniotti patent

covers Zonagen’s use of Vasomax. Accordingly, on remand the district

court will likely need to address the potential § 20(a) liability of

Blasnik and Sutter in respect to that statement.

30

Plaintiffs also complain of the district court having dismissed

the complaint with prejudice without affording them an opportunity to

(again) amend the complaint. However, at no time, either before or

after the judgment dismissing the action, did plaintiffs ever indicate

to the district court that they desired (or would desire, in the event

of dismissal), to amend the complaint; nor did they file any post

judgment motion in the district court. See, e.g., Martin v. Scott, 156

F.3d 578, 580-81 (5th Cir. 1998); Whitaker v. City of Houston, 963 F.2d

831 (5th Cir. 1992). On remand, plaintiffs may submit a request to

amend and if they do so the district court is the appropriate venue to

address in the first instance whether to allow a requested amendment.

50